Article Sidebar

pdf
Date Published: 05/05/2024
Abstract Views: 234
Views pdf: 105
DOI: https://doi.org/10.51298/vmj.v538i1.9398
Issue
Vol. 538 No. 1 (2024)
Section
Các bài báo
How to Cite
Phạm, C., Ngô, T. T., Phạm, Q. T., & Dương, Q. H. (2024). CHANGES IN SOME TYPES OF LEUKOCYTE IN PERIPHERAL BLOOD IN PATIENTS WITH HEPATOCELLULAR CARCINOMA INFECTED WITH HEPATITIS B VIRUS. Vietnam Medical Journal, 538(1). https://doi.org/10.51298/vmj.v538i1.9398

CHANGES IN SOME TYPES OF LEUKOCYTE IN PERIPHERAL BLOOD IN PATIENTS WITH HEPATOCELLULAR CARCINOMA INFECTED WITH HEPATITIS B VIRUS

Châu Phạm, Tất Trung Ngô, Quang Trung Phạm, Quang Huy Dương

Main Article Content

Abstract

Objective: To assess the changes in peripheral blood leukocyte subtypes and their correlation with tumor burden and disease stage in patients with hepatitis B virus (HBV)-infected hepatocellular carcinoma (HCC). Subjects and methods: A cross-sectional descriptive study was conducted on 178 newly diagnosed patients with HBV-infected HCC at Military Hospital 103 and Central Military Hospital 108. Peripheral blood cell analysis was performed using a laser-based cell counting method to separate different leukocyte subtypes. Results: 3,9% of patients showed a high concentration of white blood cell count, with the most common being a high concentration of Monocyte count (40,4%). Conversely, a low level of white blood cell count was observed in 7,9% of patients, with a  low concentration of Neutrophil count (N) at 3,4% and a  low level of Lymphocyte count at 5,1%. There was a significant positive correlation between Neutrophil and Monocyte counts with venous thromboembolism and disease stage (p < 0,05). Conclusion: Neutrophil and Monocyte counts are indicative markers of the body's anti-tumor immune response and may help prognosticate the disease.

Article Details

Keywords

Hepatocellular carcinoma, leukocytes, HBV infection

References

Sung H., Ferlay J., Siegel R.L. et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): 209-249.
2. Jia L., Gao Y., He Y. et al., HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res, 2020. 159: 104992.
3. Jiang Y., Han Q., Zhao H. et al., The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell Carcinoma, 2021. 8: 435-450.
4. Pan G.Q., Yang C.C., Shang X.L. et al., The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study. Eur J Med Res, 2022. 27(1): 278.
5. Marrero J.A., Kulik L.M., Sirlin C.B. et al., Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018. 68(2): 723-750.
6. Reig M., Forner A., Rimola J. et al., BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 2022. 76(3): 681-693.
7. Đỗ Trung Phấn, Một số chỉ số huyết học người Việt Nam bình thường giai đoạn 1995-2000. Bài giảng Huyết học -Truyền máu sau đại học, Nhà Xuất bản Y học, Hà Nội. 2014.
8. Fang Y., Sun X., Zhang L. et al., Hemoglobin/Red Blood Cell Distribution Width Ratio in Peripheral Blood Is Positively Associated with Prognosis of Patients with Primary Hepatocellular Carcinoma. Med Sci Monit, 2022. 28: e937146.
9. Margetts J., Ogle L.F., Chan S.L. et al., Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? Br J Cancer, 2018. 118(2): 248-257.
10. Geh D., Leslie J., Rumney R. et al., Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2022. 19(4): 257-273.